TOKYO, Feb 14 (Reuters) - Daiichi Sankyo Co. Ltd. (4568.T: Quote, NEWS , Research), Japan’s second-largest drug maker, said on Wednesday it planned to more than double its U.S. sales staff, seeking to capitalise on a wealth of new drugs expected to come to market.
